Future areas of research for IgRT with bsAb therapy in MM. ∗For example, higher IgRT dose intensity for patients who are receiving BCMA-targeted bsAbs, bsAbs in combination with other drugs, and/or concurrent lymphopenia; ^†for example, planned IgRT discontinuation once IgG troughs consistently exceed a certain threshold (eg, 400 mg/dL); ^‡for example, planned IgRT discontinuation after a fixed number of months (eg, after 6 months) or once bsAb dosing frequency is sufficiently de-escalated (eg, to once every 4 weeks or less frequently).